A randomized, placebo-controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild-type KRAS who have received first-line systemic therapy
about
Ockham's razor for the MET-driven invasive growth linking idiopathic pulmonary fibrosis and cancerTumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib.The role of cell-free DNA in predicting colorectal cancer prognosis.Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges.Targeting RAS signaling pathway as a potential therapeutic target in the treatment of colorectal cancer.Naphthazarin suppresses cell proliferation and induces apoptosis in human colorectal cancer cells via the B-cell lymphoma 2/B-cell associated X protein signaling pathway.The efficacy and safety of tivantinib in the treatment of solid tumors: a systematic review and meta-analysis.A phase I study of tivantinib in combination with temsirolimus in patients with advanced solid tumors.Targeting MET in cancer therapy.A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancerCell-Free DNA Profiling to Discover Mechanisms of Exceptional Response to Cabozantinib Plus Panitumumab in a Patient With Treatment Refractory Metastatic Colorectal Cancer
P2860
Q28067777-78E06D22-6212-4BCE-9C25-CD15586B1702Q37687269-7197F1BC-A2DC-4CF9-BE75-62C58D6B7236Q38637642-D38D42BD-4060-4E21-A5D3-05D2B4594810Q38856729-FC4E797E-25A0-4B89-8124-FBE591C61F81Q39163561-61CFC23E-78EA-42DD-8EAA-A714CE962396Q41389424-8292790D-45AC-4B27-B020-83E25445E225Q47653274-4803E27B-5BB8-468D-BDAD-8E3FBE3A982BQ49881127-37C7ED2A-6CD9-49A3-BBB3-38546A34C51FQ54987450-5AEACD77-E4BF-4FF4-99F2-41ED5147FF01Q57162835-298714D4-B4B4-4BC1-9E8D-7E61A86B984AQ58698130-3E5D6CF6-490A-416C-99EA-5AE159BB4FE5
P2860
A randomized, placebo-controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild-type KRAS who have received first-line systemic therapy
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 17 February 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A randomized, placebo-controll ...... ed first-line systemic therapy
@en
A randomized, placebo-controll ...... d first-line systemic therapy.
@nl
type
label
A randomized, placebo-controll ...... ed first-line systemic therapy
@en
A randomized, placebo-controll ...... d first-line systemic therapy.
@nl
prefLabel
A randomized, placebo-controll ...... ed first-line systemic therapy
@en
A randomized, placebo-controll ...... d first-line systemic therapy.
@nl
P2093
P2860
P921
P356
P1476
A randomized, placebo-controll ...... ed first-line systemic therapy
@en
P2093
Alberto Bessudo
Aleksey Severtsev
Bogdan Kotiv
Ellen Bolotin
Johanna C Bendell
Lothar Müller
Lowell L Hart
Mikhail V Kopp
P2860
P304
P356
10.1002/IJC.30049
P577
2016-02-17T00:00:00Z